Sunday, June 2, 2013

KRAS mutation fails to predict NSCLC chemotherapy success

Research casts doubt on the ability of the KRAS mutation to aid the selection of patients with non-small-cell lung cancer to receive adjuvant chemotherapy.

via Med Wire News
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)